Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04148391 · ClinicalTrials.gov registry record · Phase 2
NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)
A Phase 2 study of Parkinson Disease and Mild Cognitive Impairment, sponsored by Aptinyx.
- Active
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
- 20
- Study locations
NCT04148391: Active Phase 2 study of Parkinson Disease and Mild Cognitive Impairment, sponsored by Aptinyx.
NCT04148391 is a Phase 2 study of Parkinson Disease and Mild Cognitive Impairment that is active but no longer recruiting, run by Aptinyx. The registered enrollment target is 99 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04148391, a Phase 2 study of Parkinson Disease and Mild Cognitive Impairment, is active but no longer recruiting, sponsored by Aptinyx.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia
Primary Outcome
Physical examination
Conditions Studied
Interventions
- DRUG Placebo Oral Capsule
- DRUG NYX-458
Study Locations (20)
Florida
- Aptinyx Clinical Site - Boca Raton
- Aptinyx Clinical Site - Bradenton
- Aptinyx Clinical Site - Miami
- Aptinyx Clinical Site - Miami
- Aptinyx Clinical Site - Miami
- Aptinyx Clinical Site - Miami
- Aptinyx Clinical Site - Miami Lakes
- Aptinyx Clinical Site - Orlando
- Aptinyx Clinical Site - Port Charlotte
- Aptinyx Clinical Site - Port Orange
- Aptinyx Clinical Site - Sunrise
California
- Aptinyx Clinical Site - Fresno
- Aptinyx Clinical Site - Simi Valley
Arizona
- Aptinyx Clinical Site - Scottsdale
Georgia
- Aptinyx Clinical Site - Decatur
Michigan
- Aptinyx Clinical Site - Farmington Hills
Minnesota
- Aptinyx Clinical Site - Golden Valley
New Jersey
- Aptinyx Clinical Site - Toms River
New York
- Aptinyx Clinical Site - Poughkeepsie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2019-11-14 |
| Est. Completion | 2022-12-30 |
| Phase | Phase 2 |
What the registry record for NCT04148391 still lists
NCT04148391 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower).
The record links to 4 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo Oral Capsule is the first listed.
NCT04148391 names 20 study sites across 9 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT04148391 about?
NCT04148391 is a clinical study titled "NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)". A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia
What is the current status of trial NCT04148391?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2019-11-14. Estimated completion is 2022-12-30.
What conditions does trial NCT04148391 study?
This clinical trial studies the following conditions: Parkinson Disease, Mild Cognitive Impairment, Lewy Body Disease, Mild Dementia.
What interventions are being tested in trial NCT04148391?
The interventions under investigation include: Placebo Oral Capsule (DRUG), NYX-458 (DRUG).
Who is sponsoring clinical trial NCT04148391?
This trial is sponsored by Aptinyx, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04148391 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04148391's enrollment target sits among peer trials
99 92nd of 297 higher than 206 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
-
Pyridostigmine for the Treatment of Constipation in Parkinson Disease
RECRUITING · Phase 2
-
Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease
RECRUITING · Phase 2
-
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
RECRUITING · Phase 2
-
Rehabilitation of Airway Protection in Parkinson's Disease
RECRUITING · Phase 2
-
Psilocybin Therapy for Depression in Parkinson's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI